Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jan 8:10:1355027.
doi: 10.3389/fmed.2023.1355027. eCollection 2023.

Editorial: The current challenges underlying hepatitis D virus infection

Romina Salpini  1 , Valentina Svicher  1 , Patrick T Kennedy  2
Affiliations
Editorial

Editorial: The current challenges underlying hepatitis D virus infection

Romina Salpini et al. Front Med (Lausanne). .
No abstract available

Keywords: Bulevirtide; HBV; HDV; hepatocellular carcinoma; liver cirrhosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Comment on

  • Editorial on the Research Topic The current challenges underlying hepatitis D virus infection

References

    1. Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut. (2021) 70:1782–94. 10.1136/gutjnl-2020-323888 - DOI - PMC - PubMed
    1. Kamal H, Fornes R, Simin J, Stål P, Duberg AS, Brusselaers N, et al. Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: a systematic review and meta-analysis of longitudinal studies. J Viral Hepat. (2021) 28:1431–42. 10.1111/jvh.13577 - DOI - PubMed
    1. Alfaiate D, Clément S, Gomes D, Goossens N, Negro F. Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. J Hepatol. (2020) 73:533–9. 10.1016/j.jhep.2020.02.030 - DOI - PubMed
    1. Sandmann L, Wedemeyer H. Interferon-based treatment of chronic hepatitis D. Liver Int. (2023) 43:69–79. 10.1111/liv.15410 - DOI - PubMed
    1. Wedemeyer H, Aleman S, Brunetto MR, Blank A, Andreone P, Bogomolov P, et al. A phase 3, randomized trial of bulevirtide in chronic hepatitis D. N Engl J Med. (2023) 389:22–32. 10.1056/NEJMoa2213429 - DOI - PubMed

Publication types